A novel lead compound CM-118: antitumor activity and new insight into the molecular mechanism and combination therapy strategy in c-Met- and ALK-dependent cancers

  • Cancer Biol Ther. 2014 Jun 1;15(6):721-34. doi: 10.4161/cbt.28409.
Lanfang Meng  1 Mengjun Shu  2 Yaqing Chen  3 Dexiao Yang  4 Qun He  3 Hui Zhao  3 Zhiyong Feng  4 Chris Liang  5 Ker Yu  3
Affiliations
  • 1. Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China; Department of Nuclear Medicine; Zhongshan Hospital; Fudan University; Shanghai, PR China.
  • 2. School of Pharmacy; Shanghai Jiaotong University; Shanghai, PR China.
  • 3. Department of Pharmacology; Fudan University School of Pharmacy; Shanghai, PR China.
  • 4. Sundia MediTech; Shanghai, PR China.
  • 5. Xcovery Inc.; West Palm Beach, FL USA.
Abstract

The anaplastic lymphoma kinase (ALK) and the c-Met receptor tyrosine kinase play essential roles in the pathogenesis in multiple human cancers and present emerging targets for Cancer treatment. Here, we describe CM-118, a novel lead compound displaying low nanomolar biochemical potency against both ALK and c-Met with selectivity over>90 human kinases. CM-118 potently abrogated hepatocyte growth factor (HGF)-induced c-Met phosphorylation and cell migration, phosphorylation of ALK, EML4-ALK, and ALK resistance mutants in transfected cells. CM-118 inhibited proliferation and/or induced Apoptosis in multiple c-Met- and ALK-addicted Cancer lines with dose response profile correlating target blockade. We show that the CM-118-induced Apoptosis in c-Met-amplified H1993 NSCLC cells involved a rapid suppression of c-Met activity and c-Met-to-EGFR cross-talk, and was profoundly potentiated by EGFR inhibitors as shown by the increased levels of apoptotic proteins cleaved-PARP and Bim as well as reduction of the survival protein Mcl-1. Bim-knockdown or Mcl-1 overexpression each significantly attenuated Apoptosis. We also revealed a key role by mTOR in mediating CM-118 action against the EML4-ALK-dependent NSCLC cells. Abrogation of EML4-ALK in H2228 cells profoundly reduced signaling capacity of the rapamycin-sensitive mTOR pathway leading to G 1 cell cycle arrest and mitochondrial hyperpolarization, a metabolic perturbation linked to mTOR inhibition. Depletion of mTOR or mTORC1 inhibited H2228 cell growth, and mTOR inhibitors potentiated CM-118's antitumor activity in vitro and in vivo. Oral administration of CM-118 at a wide range of well tolerated dosages diminished c-Met- and ALK phosphorylation in vivo, and caused tumor regression or growth inhibition in multiple c-Met- and ALK-dependent tumor xenografts in mice. CM-118 exhibits favorable pharmacokinetic and drug metabolism properties hence presents a candidate for clinical evaluation.

Keywords
ALK; EGFR; c-Met; combination therapy; mTOR; targeted cancer therapy.
Products